Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that it appointed Dr. Aristidis Veves to the company’s Scientific Advisory Board. Dr. Veves brings more than 30 years of experience in the field of diabetic neuropathy and vascular disease. An expert in diabetic foot problems and vascular reactivity, Dr. Veves is the research director of the Joslin-Beth Israel Deaconess Foot Center and of the Microcirculation Lab, as well as an associate professor at Harvard Medical School. Dr. Veves’ research focuses on techniques that will identify patients at risk of developing diabetic foot problems at the early stages and therapeutic strategies that will prevent or slow the progression of this condition. “Dr. Veves is a highly regarded thought leader in diabetic neuropathy and vascular disease, common in patients with Critical Limb Ischemia (CLI),” said Dr. Edwin Horwitz, Chairman of Pluristem’s Scientific Advisory Board. “His appointment to our advisory board will bring invaluable expertise and perspective in diabetic neurological conditions and wound care that will be necessary as Pluristem progresses through clinical studies with its placenta-derived cell therapies.” Dr. Veves added, “Clinical results suggest that Pluristem’s product for peripheral artery disease, PLX-PAD, is potentially a safe, well tolerated and effective treatment for patients with diabetic foot and wound healing problems. I look forward to contributing to PLX-PAD’s clinical advancement as well as helping apply Pluristem’s technology to other neurological and wound care indications.” Zami Aberman, Chairman and CEO of Pluristem, added: “We at Pluristem are extremely pleased that a researcher of Dr. Veves’ caliber is joining our Scientific Advisory Board and we believe his contributions will be valuable as we enter the neurologic and wound care markets with our PLX cells.” About Pluristem Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s proprietary and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases. In April 2010, Pluristem reported interim top-line results from Phase I clinical trials of PLX-PAD that demonstrated the cell therapy is potentially safe, well tolerated and effective in patients with critical limb ischemia (CLI).
See our product animation on YouTube: Animation, the content of which is not part of this press release.Safe Harbor Statement This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we say that PLX-PAD is potentially safe, well tolerated and effective, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
For more information visit our Web site at www.pluristem.com, the content of which is not part of this press release.